On June 30, 2025, Jefferies analyst Brian Tanquilut announced an updated price target for CVS Health (CVS, Financial), raising it from $74.00 to $80.00. This revision marks an 8.11% increase from the prior target, reflecting a more optimistic outlook on the company's future performance.
Despite maintaining the current "Buy" rating, the new price target suggests confidence in the stock's potential growth. Investors tracking CVS Health (CVS, Financial) should take note of this positive adjustment as it could indicate stronger returns ahead.
CVS Health (CVS, Financial) continues to be a focal point for investors, as Jefferies' latest update aligns with their existing favorable stance on the company's stock trajectory. The updated target is set in USD, providing a clear benchmark for Wall Street observers and potential investors alike.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CVS Health Corp (CVS, Financial) is $78.55 with a high estimate of $95.00 and a low estimate of $70.00. The average target implies an upside of 14.46% from the current price of $68.63. More detailed estimate data can be found on the CVS Health Corp (CVS) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CVS Health Corp's (CVS, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CVS Health Corp (CVS, Financial) in one year is $85.23, suggesting a upside of 24.19% from the current price of $68.63. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CVS Health Corp (CVS) Summary page.
